Zoryve is under clinical development by Arcutis Biotherapeutics and currently in Pre-Registration for Psoriasis.

A new study uncovers how a novel immunotherapy prevents squamous cell carcinoma, with benefits lasting five years after treatment. This therapy is the first to activate specific components of the ...

A new study by investigators from Mass General Brigham uncovers how a novel immunotherapy prevents squamous cell carcinoma, ...